BACKGROUND: Studies in anti-neutrophil cytoplasm antibody (ANCA)-associated @entity1333 (AAV) have revealed promising biomarkers. The aim of our study was to validate the most encouraging markers of @entity2883 with @entity2883 and @entity6129 identified by literature search and to create biomarker panels. METHODS: A systematic literature review was performed and we identified 161 marker molecules that were ranked by their quantitative differential expression between active and inactive disease. Enzyme-linked immunosorbent assays were used to validate the results in a cross-sectional cohort of @entity1 with renal involvement. Active @entity1333 as assessed by the Birmingham @entity1333 Score version 3 (BVAS v3) was defined as BVAS v3 >= 1 and inactive disease as BVAS v3 = 0. Statistical analysis was performed with SPSS version 21 and the Salford Predictive Modeler 7.0 was used to generate a predictive biomarker panel. RESULTS: The review indicated abundant expression of sC5bC9, @entity4417 , @entity2242 and @entity2842 in urine, whereas granulocyte macrophage colony-stimulating factor, C-reactive protein (CRP), soluble fms-like @entity4149 kinase-1, @entity4155 ( @entity4155 ), @entity2242 , hyaluronan, @entity4417 and @entity10454 ( @entity10454 ) were identified to be highly diverse in active and inactive disease in blood samples. Our cross-sectional analysis revealed significant up-regulation of CRP, @entity2242 , @entity4417 , @entity10454 in blood and @entity2242 and @entity2842 in urine samples during active AAV (all P < 0.05). Creation of a biomarker panel comprising CRP and urinary @entity2842 yielded a sensitivity and specificity of 76% (area under the curve 0.89). CONCLUSIONS: We identified promising biomarkers in a literature-based review that were in part corroborated as has been shown for CRP, @entity4417 , @entity2242 , @entity10454 in blood and @entity2842 and @entity2242 in urine samples. Moreover, we propose a biomarker panel comprising CRP and urinary @entity2842 in @entity1 with AAV and renal involvement. Further investigations to confirm our preliminary results are clearly warranted, including the reliability to predict disease relapses.

Evaluation and validation of biomarkers in XXXX with @entity2883 and @entity6129 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1333 :: ('MESH:D014657', 'Disease') :: ['Vasculitis', 'vasculitis'] @entity10454 :: ('10068', 'Gene') :: ['IL-18BP', 'interleukin-18 binding protein'] @entity4417 :: ('718', 'Gene') :: ['C3a'] @entity6129 :: ('MESH:D055953', 'Disease') :: ['microscopic polyangiitis'] @entity2242 :: ('728', 'Gene') :: ['C5a'] @entity2842 :: ('6347', 'Gene') :: ['monocyte chemotactic protein (MCP)-1', 'MCP-1'] @entity4155 :: ('3605', 'Gene') :: ['IL-17A', 'interleukin-17A'] @entity2883 :: ('MESH:D014890', 'Disease') :: ['polyangiitis', 'granulomatosis'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine']
@entity2883 :: (MESH:D014890,Disease) :: ['granulomatosis']
